- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Authors
Keywords
Pancreatic cancer, Pancreatic adenocarcinoma, MAP kinases, Targeted therapies, MEK inhibitors, ERK, EMT, Resistance
Journal
CANCER AND METASTASIS REVIEWS
Volume 32, Issue 1-2, Pages 147-162
Publisher
Springer Nature
Online
2012-10-20
DOI
10.1007/s10555-012-9396-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
- (2015) William H. Chappell et al. Oncotarget
- Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
- (2012) J. B. Bachet et al. ANNALS OF ONCOLOGY
- Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling
- (2012) Annette S. Little et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Roles of p38 MAPKs in invasion and metastasis
- (2012) Ivan del Barco Barrantes et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
- (2012) S V Holt et al. BRITISH JOURNAL OF CANCER
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis
- (2012) Guopei Luo et al. PANCREATOLOGY
- Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib
- (2012) Sandrine Faivre et al. Targeted Oncology
- Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation
- (2011) H. Wang et al. CANCER RESEARCH
- Smad phosphoisoform signaling specificity: the right place at the right time
- (2011) Koichi Matsuzaki CARCINOGENESIS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition
- (2011) M. E. Urick et al. CLINICAL CANCER RESEARCH
- Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells
- (2011) C. H. Diep et al. CLINICAL CANCER RESEARCH
- Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis
- (2011) Yannick Delpu et al. CURRENT GENOMICS
- MEK inhibitors: a patent review 2008 – 2010
- (2011) John I Trujillo EXPERT OPINION ON THERAPEUTIC PATENTS
- Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology
- (2011) Pawel K Mazur et al. GUT
- A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
- (2011) A. B. El-Khoueiry et al. INVESTIGATIONAL NEW DRUGS
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
- (2011) J. Jing et al. MOLECULAR CANCER THERAPEUTICS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raf kinases in cancer–roles and therapeutic opportunities
- (2011) G Maurer et al. ONCOGENE
- Molecular Pathogenesis of Pancreatic Cancer and Clinical Perspectives
- (2011) D. Matthaios et al. ONCOLOGY
- Clinical Potential of MicroRNAs in Pancreatic Ductal Adenocarcinoma
- (2011) Colin W. Steele et al. PANCREAS
- Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma
- (2011) Adriana Handra-Luca et al. PANCREAS
- Pancreatic Cancer: The Role of Pancreatic Stellate Cells in Tumor Progression
- (2011) Siri Dunér et al. PANCREATOLOGY
- Epithelial-to-Mesenchymal Transition in Pancreatic Adenocarcinoma
- (2011) Carla Cano et al. TheScientificWorldJOURNAL
- Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer
- (2010) Howard Safran et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The Ras-ERK pathway: Understanding site-specific signaling provides hope of new anti-tumor therapies
- (2010) Fernando Calvo et al. BIOESSAYS
- Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts
- (2010) Qing Chang et al. BMC CANCER
- A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
- (2010) Andrey Loboda et al. BMC Medical Genomics
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models
- (2010) Qing Chang et al. CANCER BIOLOGY & THERAPY
- Kinase signaling pathways as targets for intervention in pancreatic cancer
- (2010) Meir Preis et al. CANCER BIOLOGY & THERAPY
- Germline Brca2 Heterozygosity Promotes KrasG12D -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer
- (2010) Ferdinandos Skoulidis et al. CANCER CELL
- The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines
- (2010) Ravi P. Sahu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Emerging MEK inhibitors
- (2010) James A McCubrey et al. EXPERT OPINION ON EMERGING DRUGS
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
- (2010) Hedy Lee Kindler et al. INVESTIGATIONAL NEW DRUGS
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia Induced Tumor Metabolic Switch Contributes to Pancreatic Cancer Aggressiveness
- (2010) Sophie Vasseur et al. Cancers
- Targeting the RAF–MEK–ERK pathway in cancer therapy
- (2009) Clara Montagut et al. CANCER LETTERS
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Emerging Raf inhibitors
- (2009) James A McCubrey et al. EXPERT OPINION ON EMERGING DRUGS
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion
- (2009) Wenhu Huang et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer
- (2009) J. J. Yeh et al. MOLECULAR CANCER THERAPEUTICS
- Pancreatic cancer: molecular pathogenesis and new therapeutic targets
- (2009) Han H. Wong et al. Nature Reviews Gastroenterology & Hepatology
- Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
- (2009) Joanna M. Brell et al. ONCOLOGY
- Targeted therapies for pancreatic cancer
- (2008) S. A. Danovi et al. BRITISH MEDICAL BULLETIN
- Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
- (2008) Antoun Toubaji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation
- (2008) George Fountzilas et al. CANCER INVESTIGATION
- Inhibition of STAT3Tyr705 Phosphorylation by Smad4 Suppresses Transforming Growth Factor -Mediated Invasion and Metastasis in Pancreatic Cancer Cells
- (2008) S. Zhao et al. CANCER RESEARCH
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells
- (2008) Joe W. Ramos INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
- (2008) S. A. Lang et al. MOLECULAR CANCER THERAPEUTICS
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More